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Introduction
Hyponatraemia is the commonest electrolyte 
imbalance in clinical practice. It is defined 
as a sodium concentration of less than 
135mmol/l. In 2014, Clinical Practice 
Guidelines1 on the diagnostic approach and 
treatment of hyponatraemia were published 
as a joint venture of 3 major European 
societies representing specialists with a 
natural interest in hyponatraemia. The 
American recommendations on diagnosing, 
evaluating and treating hyponatraemia2, 
published in 2013, are similar in many 
aspects, but they do differ in others, 
especially in management. This article 
reviews the diagnosis and management of 
hyponatraemia according to the European 
Clinical practice guidelines, highlighting any 
discrepancies between the European and 
American views.
Pathophysiology
Hyponatraemia is primarily a disorder of 
water balance, with a relative excess of body 
water compared to total body sodium and 
potassium content. The major mechanisms 
responsible for regulating water metabolism 
are thirst and the pituitary secretion and 
renal effects of arginine vasopressin (AVP; 
antidiuretic hormone, ADH). When serum 
osmolality starts to rise, osmoreceptive 
neurons located in the anterior hypothalamus 
detect a decrease in cell stretch which in 
turn leads to increased thirst and increased 
release of AVP from the posterior pituitary 
gland.3  
In the left atrium, carotid sinus and 
aortic arch, there are stretch-sensitive 
receptors (baroreceptors) that sense 
circulating volume. When the volume 
decreases, afferent neural impulses decrease 
and AVP secretion increases4. AVP, then, 
regardless of the stimulus, binds to the 
AVP V2 receptor subtype in the collecting 
duct of the kidney and activates the 
signal transduction cascade resulting 
in antidiuresis, with urine being more 
concentrated.
Classification of hyponatraemia
There are three classifications of 
hyponatraemia based on:
1 Severity;
2 Symptoms;
3 Rate of development.
The first classification is based on the 
level of serum sodium, with cut-offs below 
125mmol/l regarded as profound, levels 
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Abstract
Hyponatraemia, defined as a sodium concentration <135mmol/l, is the 
most common electrolyte imbalance encountered in clinical practice. 
Symptoms can range from seemingly asymptomatic to severe and even 
life-threatening. Hyponatraemia is usually managed by clinicians from 
various fields, leading to a wide variety of approaches to its diagnosis 
and treatment.
Educational aims
•	 To highlight the importance of treating hyponatraemia, even if chronic and not 
associated with obvious clinical features
•	 To increase familiarity with the common causes and diagnosis of hyponatraemia
•	 To update the knowledge on management of hyponatraemia including the use of novel 
drug therapy
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between 125 and 129mmol/l moderate and 
levels above 130mmol/l being mild. 
Symptoms can range from seemingly 
asymptomatic, with subtle clinical findings 
such as a gait disturbances, falls, mild 
cognitive deficits5 and osteoporosis to more 
severe. In one study, the prevalence of 
hyponatremia in a group of patients with 
a verified bone fracture was significantly 
higher than a control group who had no 
history of bone fracture6.  In another 
study it was found that the occurrence of 
all forms of hyponatraemia on admission 
were associated with increased in-hospital 
mortality and added pressure on the 
hospital’s limited resources. Moderately 
severe symptoms include confusion, nausea 
or headache whereas severe symptoms 
may include vomiting, seizures or coma. 
Symptoms are very non-specific, so a 
diagnosis of hyponatraemia should not rely 
on symptoms alone.
The third classification is based on the 
time of development, with 48 hours being 
the cut-off for differentiating acute from 
chronic. This classification is based on 
the fact that in the presence of hypotonic 
hyponatraemia, water shifts from the 
hypotonic extracellular to the intracellular 
compartment across an osmotic gradient, 
causing brain oedema. This is associated 
with the severe symptoms of hyponatraemia. 
This seems to occur more frequently when 
hyponatraemia develops in less than 48 
hours because the brain has had too little 
time to adapt to its hypotonic environment. 
After 24 to 48 hours, the brain reduces the 
number of osmotically active particles within 
its cells, mainly potassium and organic 
solutes in an attempt to restore brain 
volume.8
Pitfalls in diagnosis
Once biochemical hyponatraemia is 
confirmed, non-hypotonic hyponatraemia 
should be excluded. One of the commonest 
causes is hyperglycaemia. When solutes 
which are impermeable to the cell membrane 
are present in excess in the extracellular 
compartment, an osmotic pressure gradient 
is created across the cell membranes, 
leading to osmotic movement of water 
from the intracellular to the extracellular 
compartment. This causes dilutional 
hyponatraemia with a water shift from the 
intra to the extracellular compartment, so 
posing no risk of brain oedema. 
Pseudohyponatraemia is a laboratory 
artefact that occurs when an abnormally high 
concentration of serum lipids or proteins 
interfere with the accurate measurement of 
sodium9. 
Differentiating causes of hypotonic 
hyponatraemia
Once hypo-tonic hyponatraemia is confirmed, 
measurement of a spot urine osmolality 
and sodium will help diagnose the cause of 
hyponatraemia (Figure 1).
Treatment of hypotonic hyponatraemia
Acute and/or symptomatic  hyponatraemia
If hyponatraemia is associated with symptoms, 
treatment should be initiated immediately and 
this involves the infusion of 3% hypertonic 
saline. Hypertonic saline is listed as a high 
alert medication by the institute for safe 
medication practice (ISMP)10. Such drugs 
bear a heightened risk of causing significant 
patient harm when  used in error. Preparing 
this infusion takes time and meticulous 
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Figure 1: Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski G et al European Journal of Endocrinology: 2014: 17:3 G1-G47. Copyright © 2014, European Society of Endocrinology
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Chronic hyponatraemia with reduced 
extracellular fluid volume
In these scenarios, intravenous infusion 
of 0.9% sodium chloride or any crystalloid 
should be infused and cause-specific 
treatment started (Figure 1). In patients 
with haemodynamic instability, the need for 
rapid intravenous fluid resuscitation may 
override the risk of an overly rapid increase 
in sodium concentration. Cause specific 
treatment should be initiated as soon as the 
precipitating factor is identified.
Chronic hyponatraemia with normal 
extracellular fluid volume
Syndrome of inappropriate antidiuresis 
(SIAD)
Syndrome of inappropriate antidiuresis is 
a syndrome in which production of AVP is 
independent of the stimuli described above. 
(Figure 1) It results either from an increased 
release by the pituitary, or an ectopic 
source or from an increased sensitivity of 
the collecting duct to vasopressin. Table 1 
defines the diagnostic criteria for diagnosing 
SIAD. Common causes for SIAD include:
•	 Malignancies especially lung and 
gastrointestinal;
•	 Pulmonary diseases;
•	 Central nervous system associated 
diseases;
•	 Drugs (Table 2);
•	 Idiopathic.
Treatment includes fluid restriction as 
first line. Other options for treatment include 
high solute intake with urea but this should 
be combined with sweet-tasting substances to 
mask the bitter taste of urea. Other treatment 
options include vasopressin receptor 
antagonists (vaptans) and Demeclocycline. 
In the United States2, vaptan use may be 
considered in select circumstances, namely, 
an inability to tolerate fluid restriction 
or predicted failure of fluid restriction. In 
normal physiological states, AVP binds to 
V2 receptors in the collecting duct and an 
intracellular cascade is activated, resulting 
in the collecting duct being more permeable 
to water, thus retaining more water. Vaptans 
bind to these V2 receptors, blocking the 
action of AVP, thus rendering the collecting 
duct less permeable to water. This leads 
to an increased urine output which is 
solute-sparing, in contrast to loop diuretics 
which block sodium transporters, leading to 
simultaneous electrolyte and water loss. For 
this reason, the vaptans have been termed 
aquaretics. 
In one systematic review, vaptans 
were found to increase serum sodium 
concentration modestly, but there was no 
Table 1: Criteria for diagnosis SIAD
Serum osmolality <270mOsm/kg
Inappropriate urine osmolality >100mOsm/kg
Renal sodium >30mmol/l
Euvolaemia
Normal renal, adrenal, and thyroid function
Table 2: Drugs associated with SIAD
Psychiatric drugs Selective serotonin reuptake inhibitors 
(SSRIs)
Tricyclic
Monoamine oxidase inhibitors (MAOIs)
Antipsychotics
Anticonvulsants Carbamezapine
Sodium valproate
Lamotrigine
Chemotherapy Vincristine
Vinblasitne
Cyclophosphamide
Antidiabetic drugs Chlorpropamide
Tolbutamine
Others Opiates
Interferon
Proton pump inhibitors
Non-steroidal anti-inflammatory drugs 
(NSAIDS)
Amiodarone
Vasopressin analogues Desmopressin
Oxytocin
Terlipressin
Vasopressin
attention should be taken to avoid errors when 
calculating the required amount of sodium 
chloride. Administration of hypertonic saline 
should be done in environments where strict 
clinical and biochemical supervision can be 
undertaken.
Rate of correction of sodium is of utmost 
importance and the recommended rate of 
increase in serum sodium concentration is of 
a total of 10mmol/l during the first 24 hours 
and an additional 8mmol/l per day thereafter 
until sodium concentration reaches 130mmol/
l1. More rapid correction of serum sodium 
may lead to osmotic demyelination syndrome 
(ODS). This is a neurological disease caused 
by severe damage to the myelin sheath of 
nerve cells in the brain, which has serious 
neurological sequele11. Patients who are at 
increased risk of developing ODS include, 
alcohol abusers, patients with liver disease, 
use of thiazides or antidepressant medication, 
serum sodium <105mmol/l and hypokalaemia. 
In such patients, special caution should be 
taken in correcting their hyponatraemia.
Chronic hyponatraemia
In this scenario, the focus should be on trying 
to identify and treat the precipitating factor, 
rather than treating the hyponatraemia per se. 
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significant reduction in risk of death12. Also 
the risk of rapid increase in sodium was 
2.5 times higher than when treated with 
placebo (relative risk 2.52, 95% CI 1.26-
5.06). However there were no reports of 
osmotic demyelination syndrome. Tolvaptan, 
one of the vaptans, was studied in patients 
with autosomal dominant polycystic kidney 
disease13 and the tolvapan treatment 
group was noted to have an elevation of 
alanine aminotransferase greater than three 
times the upper limit of normal. But doses 
administered in these patients were higher 
than those used in hyponatraemia.
Demeclocycline is a tetracycline 
derivative and it causes a form of 
nephrogenic diabetes insipidus, irrespective 
of the serum AVP level14. Treatment must 
be continued for several days to achieve 
maximal diuretic effect and dose should not 
be increased before 3-4 days have passed. 
Side effects of this drug include azotaemia, 
photosensitive skin rash and sometimes 
nephrotoxicity, especially in patients with 
cirrhosis. Therefore, renal function should be 
monitored on a regular basis. 
Chronic hyponatraemia with expanded 
extracellular fluid volume 
In these conditions, diuretic therapy 
and dietary sodium restriction form the 
mainstay of therapy2. Fluid restriction may 
compliment this. Vaptans may be used in a 
subset of patients in whom hyponatraemia 
is limiting diuretic use or in whom there 
are mild symptoms thought to be due to 
hyponatraemia2.  The European Guidelines 
are more cautious in the use of vaptans, and 
in fact recommend against their use (See 
Figure 1) 1. 
Conclusion
Treatment of acute hyponatraemia can be 
life-saving in some circumstances, although 
care should be taken to avoid correcting 
hyponatraemia too rapidly. Vaptan use may 
become a cornerstone in the treatment of 
hyponatraemia in the near future, although 
more data regarding its safety is awaited. 
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